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Abstract 
Primary hyperparathyroidism (PHPT) is the third most common endocrine disorder 
characterized by autonomous parathyroid hormone (PTH) secretion by one or more 
parathyroid glands and increased serum calcium concentration. A recent genome wide 
association study showed that the rs6127099 polymorphism, which is located upstream 
the CYP24A1 (Cytochrome P450, family 24, subfamily A, polypeptide 1) gene, is 
associated strongly with elevated serum PTH levels. CYP24A1 gene encodes an 
enzyme of cytochrome P450, which is responsible for inactivating vitamin D 
metabolites. As PTH hypersecretion is a common clinical sign of PHPT, the aim of the 
present study was to investigate the role of the polymorphism rs6127099 as a genetic 
predisposing factor for PHPT manifestation. Thirty-nine unrelated patients with 
sporadic PHPT and an equal number of healthy volunteers were enrolled in the study. 
Polymerase chain reaction and restriction fragment length polymorphism assays were 
used for rs6127099 genotyping in both groups. No statistically significant difference 
was observed comparing CYP24A1 rs6127099 A>T genotypes (p = 0.836) and A vs T 
allele (p = 0.383) distribution between PHPT patients and controls. In conclusion, 
rs6127099 polymorphism seems not to be associated with PHPT predisposition. Further 
independent studies, as the present one, are necessary to evaluate the strong association 
of rs6127099 polymorphism with PTH levels and its prognostic role in PHPT 
predisposition. 
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Parathyroid hormone (PTH) is secreted 
by parathyroid glands and it is the key 
calcium regulatory hormone in humans. 
The physiologic role of PTH is to 
maintain serum calcium concentration 
in blood by increasing bone resorption, 
enhancing calcium reabsorption in 
kidneys and stimulating the synthesis of 
the active vitamin D –(1,25-
dihydroxyvitamin D3) from the inactive 
form (25-hydroxyvitamin D3). Active 
vitamin D acts on kidneys and intestines 
to enhance calcium reabsorption and 
absorption, respectively. Subsequently, 
the restored serum Ca2+ provides a 
negative feedback signal to the 
parathyroid glands, discontinuing the 
release of PTH (Khundmiri, Murray 
and Lederer, 2016; Jeon, 2018).  
Primary Hyperparathyroidism (PHPT) 
is an endocrine disorder characterized 
by autonomous production of 
parathyroid hormone (PTH) from one 
or more parathyroid gland(s) and 
among others is presented with 
hypercalcemia. It is the third most 
common endocrine clinical disorder 
with a prevalence between 0.1-1.0% 
and an increasing incidence with age 
which peaks between 50 and 60 year 
olds (Gopinath and Mihai, 2011; 
MacKenzie-Feder et al., 2011; 
Madkhali et al., 2016). The vast 
majority of cases (90-95%) are sporadic 
and PHPT is caused from a single 
parathyroid adenoma in most cases (80-
85%) and rarely from multiglandular 
parathyroid hyperplasia (<15%) and 
parathyroid carcinoma (<1%) (Pallan, 
Rahman and Khan, 2012; Madkhali et 
al., 2016). Approximately 5% of cases 
of PHPT are familial, associated with 
genetic syndromes such as multiple 
endocrine neoplasia (MEN) type 1, 2A 
or 4 and hyperparathyroidism-jaw 
tumor syndrome (HPT-JT), while less 
frequently PHPT cases do not show any 
syndromic association as happen in 
familial isolated hyperparathyroidism 
(FIHPT), familial hypocalciuric 
hypercalcaemia (FHH), neonatal severe 
hyperparathyroidism (NSHPT) and 
autosomal dominant moderate 
hyperparathyroidism (ADMH) 
(Gopinath and Mihai, 2011; Iacobone et 
al., 2015).  
The genetic basis of sporadic PHPT is 
complicated and a number of genes has 
been reported to be involved in the 
disease, including cell regulatory genes 
(Cyclin D1-CCND1, Menin1- MEN1), 
genes of the Wnt/β-catenin pathway 
and, apoptotic and growth factor genes 
(Mizamtsidi et al., 2018). As 
parathyroid hormone production and 
serum calcium levels are increased in 
PHPT, genes involved in calcium 
homeostasis could also be genetic 
candidate factors for the disease. 
Mutations in CaSR (Calcium Sensing 
Receptor) and VDR (Vitamin D 
Receptor) genes have been reported to 
be associated with PHPT, but in most 
cases this association is restricted in 
certain population groups or in certain 
PHPT symptoms (Carling et al., 1997; 
Yamauchi et al., 2001; Christensen et 
al., 2013; Vezzoli et al., 2014; Wang et 
al., 2016; Matana, Popović, et al., 
2018), which means that the role of 
calcium homeostasis genes in PHPT 
needs more investigation.  
Recently, a genome wide association 
study (GWAS) showed that rs6127099 
polymorphism, that lies 38 kbp 
upstream of CYP24A1 (Cytochrome 
P450, family 24, subfamily A, 
polypeptide 1) gene, is associated with 
elevated PTH serum levels (Robinson-
Cohen et al., 2017). CYP24A1 gene 
(20q13) encodes the cytochrome P450 
component of the 25-hydroxyvitamin 
D3-24-hydroxylase enzyme which 
catalyzes the degradation of the vitamin 
D molecule by converting 25-
hydroxyvitamin D3 and 1,25-
dihydroxyvitamin D3 into 24-
hydroxylated products (Jones, Prosser 
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and Kaufmann, 2012). Taking into 
account that PTH serum concentration 
is high in PHPT patients, the aim of the 
present study was to evaluate the 
potential role of rs6127099 
polymorphism as a genetic risk factor 
for PHPT.  
 
Materials and Methods 
Thirty-nine unrelated patients with 
PHPT (2 males and 37 females; mean 
age 52.6 ± 14.3 years; range 29–74 
years) were enrolled in the study. The 
diagnosis of PHPT was made by the 
elevated PTH and calcium levels in 
blood serum and was established with at 
least two imaging methods 
(sonography, 99mTc-sestamibi 
scintigraphy, 4D-CT). In addition, 39 
ethnic matching healthy volunteers (2 
males and 37 females; mean age 49.1 ± 
18.8 years; range 20–85 years) with no 
personal or family history of chronic 
autoimmune or neoplastic diseases 
were studied. The samples sizes were 
calculated using an online calculator 
(http://www.pilotsamplesize.com) 
designed for pilot trials, as the present 
study, setting an 85% upper confidence 
level and probability at 0.05 
(Viechtbauer et al., 2015).  
This study adhered to the tenets of the 
declaration of Helsinki (version 2002) 
and approved was by the Ethics 
Committees of Aristotle University of 
Thessaloniki (approval number 498/17-
7-2019). Written consent was obtained 
from each participant in the study. 
Genomic DNA was extracted from 
peripheral blood lymphocytes using the 
PureLink Genomic DNA Kit 
(Invitrogen). Polymorphism rs6127099 
was studied with restriction fragment 
length polymorphism (RFLP) assay. 
The primer pair F: 5’-
TCCAGAACACCAGACCAGGG-3’, 
R:5’GAGCATCCCTTAGTGGGCAT
T-3’ was used for the amplification of 
rs6127099 polymorphism. The 
restriction assay was performed using 
the PstI restriction endonuclease (New 
England Biolabs). All samples were run 
twice.  
SPSS statistical package (SPSS Inc.) 
was used to test differences in 
polymorphism distribution between 
PHPT patients and controls (Pearson's 
chi‐square, Yates’ chi‐square if any 
expected frequency was below 1 or if 
the expected frequency was <5 in more 
than 20% of cells). Furthermore, the 
odds ratio (OR) with a confidence 
interval (CI) of 95% was calculated 
(reference allele vs variant allele). A 
difference at P ≤ 0.05 was considered as 
statistically significant.  
 
Results 
The distribution of genotypes of 
rs6127099 polymorphism in PHPT 
patients and controls is shown in Table 
1. No statistical significant difference 
was observed in the distribution of 
rs6127099 A>T genotypes distribution 
between PHPT patients and controls  
(p = 0.836). Similarly, no statistical 
significant difference was observed 
comparing rs6127099 A allele vs. T 
allele distribution between the studied 
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Table 1. Statistical analysis of rs6127099 polymorphism between PHPT patients 
and controls  
rs6127099 
Genotypes AA AT TT  
Patients   (n=39) 16 20 3 χ2 = 0.888,  df = 2 
p-value = 0.642 
p-value = 0.836 (yates’ 
correction) 
Control group (n=39) 20 17 2 
Alleles A T  
Patients   (n=78) 52 26 χ2 = 0.761,  df = 1 
p-value = 0.383 
OR: 0.739, 95%CI: 0.371-
1.465 
Control group (n=78) 57 21 
df: degrees of freedom; OR: odds ratio; 95% CI: 95% confidence interval 
 
Discussion 
PHPT is an endocrine disorder 
characterized by increased serum PTH 
and calcium concentration. Genes 
involved in calcium homeostasis 
regulation may have a role in the 
genetic basis of the disease. CYP24A1 
gene, which encodes a monoxygenase 
of cytochrome P450, catalyzes the 
inactivation of 25-hydroxyvitamin D3 
and 1,25-dihydroxyvitamin D3 
preventing the toxicity of vitamin D 
(Jones, Prosser and Kaufmann, 2012). 
Loss of function CYP24A1 mutations 
cause severe childhood 
hypercalcaemia, adult hypercalcaemic 
syndrome and nephrolithiasis, with 
potent PTH suppression (Schlingmann 
et al., 2011; Dauber et al., 2012; 
Nesterova et al., 2013; Molin et al., 
2015). Polymorphism rs6127099 lies 
38 kbp upstream of CYP24A1 gene. 
The T allele of rs6127099 was 
 
associated with higher serum PTH 
concentration, suggesting that this 
allele may provide increased CYP24A1 
activity, accelerated catabolism of 1,25-
dihydroxyvitamin D3 and increased 
PTH levels (Robinson-Cohen et al., 
2017).  
The present study focused on the role of 
rs6127099 as a candidate genetic risk 
factor for PHPT. Although serum PTH 
hypersecretion is a major clinical 
manifestation of PHPT, no association 
of rs6127099 polymorphism with the 
disease was found. Previously, in a 
GWAS, PTH concentration was 
strongly associated with polymorphism 
rs6127099 (p =4.2 x 10-53) (Robinson-
Cohen et al., 2017). However, the 
present study for first time validates the 
reported association and its clinical use 
in a disorder which is characterized by 
high PTH levels. The evaluation of 
GWAS results in random small sample 
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groups is of great importance when 
searching for true disease risk factors, 
as many times the results of GWAS 
have limited clinical predictive value 
and other limitations (Kraft, Zeggini 
and Ioannidis, 2009; Tam et al., 2019). 
Therefore, even the results of a negative 
association, as these of the present 
study, offers to the suggested probable 
use of a polymorphism as a biomarker 
in a disease predisposition. 
Polymorphism rs6127099 is located in 
an intergenic DNA region that does not 
have any known function, i.e. in a 
coding or regulatory gene sequence 
according to the national databases. So, 
it is possible that this polymorphism 
does not have any effect on CYP24A1 
gene. This seems to be consistent with 
the results of the present study, but as 
mentioned before it contradicts the 
results of the genome wide association 
study (Robinson-Cohen et al., 2017), 
which argues that the allele T of this 
polymorphism rs6127099 is related to 
high PTH serum levels. However, 
rs6127099 was reported to be in linkage 
disequilibrium with the variant 
rs1570669, which has been also 
associated with high PTH levels, lower 
circulating calcium and reduced bone 
mineral density (BMD) at the femoral 
neck (O’Seaghdha et al., 2013). 
Therefore, further studies are needed to 
enlighten the causative variant in PTH 
levels. 
Additionally, it is estimated that 60% of 
the variation in PTH concentration is 
genetically determined (Hunter et al., 
2001). PTH levels are regulated by 
many genetic loci. Polymorphisms 
associated with increased PTH 
concentration have also been found in 
other genes, such as in RGS14 
(Regulator Of G Protein Signaling 14), 
CLDN14 (Claudin 14), RTDR1 
(Rhabdoid Tumor Deletion Region 
Gene 1), RASGEF1B (RasGEF 
Domain Family Member 1B) and 
DPP10 (Dipeptidyl Peptidase Like 10) 
(Robinson-Cohen et al., 2017; Matana, 
Brdar, et al., 2018). Polymorphisms 
associated with PHPT manifestation 
have also been found in CaSR and VDR 
genes (Carling et al., 1997; Yamauchi et 
al., 2001; Christensen et al., 2013; 
Vezzoli et al., 2014; Wang et al., 2016; 
Matana, Popović, et al., 2018), while 
epigenetic alterations have also been 
reported to play a role (Sulaiman et al., 
2013; Westin, 2016). Therefore, PTH 
levels in patients with PHPT may 
represent the interplay of many genes 
and their variants. Concluding, one 
limitation of the present study is the 
small sample size, which reduces the 
study’s statistical power and may lead 
to a type II statistical error. This means 
that the association may exist in the 
population, but the small sample size 
may not permit it to be detected. 
However, the low prevalence of the 
disease may excuse our PHPT patient 
sample size and give value to our 
preliminary results. Therefore, the 
present pilot study of Greek origin, 
emphasizes the need for additional 
studies in larger groups of patients of 
various ethnicities to validate the 
reported association of rs612099 
polymorphism with the high PTH levels 
and probably with PHPT 
predisposition.  
 
Conflict of interest 




Carling, T. et al. (1997) ‘Vitamin D 
receptor alleles b, a, and t: Risk factors 
for sporadic primary 
hyperparathyroidism (HPT) but not 
HPT of uremia or MEN 1’, Biochemical 
and Biophysical Research 
Communications, 231(2), pp. 329–332. 
doi: 10.1006/bbrc.1997.6086. 
 
Christensen, M. H. E. et al. (2013) 
‘1,25-Dihydroxyvitamin D and the 
Aristotle Biomedical Journal, Vol 3, No 2 e-ISSN: 2653-9748 
7 
 
Vitamin D Receptor Gene 
Polymorphism Apa1 Influence Bone 
Mineral Density in Primary 
Hyperparathyroidism’, PLoS ONE, 
8(2).doi:10.1371/journal.pone.0056019 
 
Dauber, A. et al. (2012) ‘Genetic defect 
in CYP24A1, the vitamin D 24-
hydroxylase gene, in a patient with 
severe infantile hypercalcemia’, Journal 
of Clinical Endocrinology and 
Metabolism, 97(2), pp. 268–274. doi: 
10.1210/jc.2011-1972. 
 
Gopinath, P. and Mihai, R. (2011) 




Hunter, D. et al. (2001) ‘Genetic 
contribution to bone metabolism, 
calcium excretion, and vitamin D and 
parathyroid hormone regulation’, 
Journal of Bone and Mineral Research, 
16(2), pp. 371–378. doi: 
10.1359/jbmr.2001.16.2.371. 
 
Iacobone, M. et al. (2015) ‘Hereditary 
hyperparathyroidism—a consensus 
report of the European Society of 
Endocrine Surgeons (ESES)’, 
Langenbeck’s Archives of Surgery, 
400(8), pp. 867–886. doi: 
10.1007/s00423-015-1342-7. 
 
Jeon, S. (2018) ‘Exploring vitamin D 
metabolism and function in cancer’, 
Experimental & Molecular Medicine. 
Springer US. doi: 10.1038/s12276-018-
0038-9. 
 
Jones, G., Prosser, D. E. and Kaufmann, 
M. (2012) ‘25-Hydroxyvitamin D-24-
hydroxylase (CYP24A1): Its important 
role in the degradation of vitamin D’, 
Archives of Biochemistry and 
Biophysics. Elsevier Inc., 523(1), pp. 
9–18. doi: 10.1016/j.abb.2011.11.003. 
 
Khundmiri, S. J., Murray, R. D. and 
Lederer, E. (2016) ‘PTH and vitamin 
D’, Comprehensive Physiology, 6(2), 
pp. 561–601. doi: 
10.1002/cphy.c140071. 
 
Kraft, P., Zeggini, E. and Ioannidis, J. 
P. A. (2009) ‘Replication in genome-
wide association studies.’, Statistical 
science : a review journal of the 
Institute of Mathematical Statistics, 
24(4), pp. 561–573. doi: 10.1214/09-
STS290. 
 
MacKenzie-Feder, J. et al. (2011) 
‘Primary hyperparathyroidism: An 
overview’, International Journal of 
Endocrinology, 2011. doi: 
10.1155/2011/251410. 
 
Madkhali, T. et al. (2016) ‘Primary 
hyperparathyroidism’, Turkish Journal 
of Surgery, 32(1), pp. 58–66. doi: 
10.5152/UCD.2015.3032. 
 
Matana, A., Popović, M., et al. (2018) 
‘Effects of genetic variants on serum 
parathyroid hormone in 
hyperparathyroidism and end-stage 
renal disease patients: A systematic 
review and meta-analysis’, Medicine 
(United States), 97(21). doi: 
10.1097/MD.0000000000010834. 
 
Matana, A., Brdar, D., et al. (2018) 
‘Genome-wide meta-analysis identifies 
novel loci associated with parathyroid 
hormone level’, Molecular Medicine, 
24(1), pp. 1–9. doi: 10.1186/s10020-
018-0018-5. 
 
Mizamtsidi, M. et al. (2018) ‘Diagnosis, 
management, histology and genetics of 
sporadic primary hyperparathyroidism: 
Old knowledge with new tricks’, 
Endocrine Connections, 7(2), pp. R56–
R68. doi: 10.1530/EC-17-0283. 
 
 
Aristotle Biomedical Journal, Vol 3, No 2 e-ISSN: 2653-9748 
8 
 
Molin, A. et al. (2015) ‘CYP24A1 
mutations in a cohort of hypercalcemic 
patients: Evidence for a recessive trait’, 
Journal of Clinical Endocrinology and 
Metabolism, 100(10), pp. E1343–
E1352. doi: 10.1210/jc.2014-4387. 
 
Nesterova, G. et al. (2013) ‘1,25-
(OH)2D-24 hydroxylase (CYP24A1) 
deficiency as a cause of 
nephrolithiasis’, Clinical Journal of the 
American Society of Nephrology, 8(4), 
pp. 649–657. doi: 
10.2215/CJN.05360512. 
 
O’Seaghdha, C. M. et al. (2013) ‘Meta-
analysis of genome-wide association 
studies identifies six new Loci for 
serum  calcium concentrations.’, PLoS 
genetics, 9(9), p. e1003796. doi: 
10.1371/journal.pgen.1003796. 
 
Pallan, S., Rahman, M. O. and Khan, A. 
A. (2012) ‘Diagnosis and management 
of primary hyperparathyroidism’, BMJ 
(Online), 344(7849), pp. 1–8. doi: 
10.1136/bmj.e1013. 
 
Robinson-Cohen, C., Lutsey, P. L., 
Kleber, M. E., Nielson, C. M., Mitchell, 
B. D., Bis, J. C., Eny, K. M., Portas, L., 
Eriksson, J., Lorentzon, M., Koller, D. 
L., Milaneschi, Y., Teumer, A., Pilz, S., 
Nethander, M., Selvin, E., Tang, W., 
Weng, L.-C., Wong, H. S., et al. (2017) 
‘Genetic Variants Associated with 
Circulating Parathyroid Hormone.’, 
Journal of the American Society of 
Nephrology : JASN, 28(5), pp. 1553–
1565. doi: 10.1681/ASN.2016010069. 
 
Schlingmann KP , Kaufmann M, Weber 
S, Irwin A, Goos C, John U, Misselwitz 
J, Klaus G, Kuwertz-Bröking E, 
Fehrenbach H, Wingen AM, Güran T, 
Hoenderop JG, Bindels RJ, Prosser DE, 
Jones G, Konrad M. (2011) ‘Mutations 
in CYP24A1 and idiopathic infantile 
hypercalcemia.’ N Engl J Med, 365(5), 
pp.410-421. 
Sulaiman, L. et al. (2013) ‘Global and 
gene-specific promoter methylation 
analysis in primary 
hyperparathyroidism’, Epigenetics, 








Tam, V. et al. (2019) ‘Benefits and 
limitations of genome-wide association 
studies.’, Nature reviews. Genetics. 
England, 20(8), pp. 467–484. doi: 
10.1038/s41576-019-0127-1. 
 
Vezzoli, G. et al. (2014) ‘Risk of 
nephrolithiasis in primary 
hyperparathyroidism is associated with 
two polymorphisms of the calcium-
sensing receptor gene’, Journal of 
Nephrology, 28(1), pp. 67–72. doi: 
10.1007/s40620-014-0106-8. 
 
Viechtbauer, W. et al. (2015) ‘A simple 
formula for the calculation of sample 
size in pilot studies’, Journal of Clinical 




Wang, X. M. et al. (2016) 
‘Polymorphisms of CASR gene 
increase the risk of primary 
hyperparathyroidism’, Journal of 
Endocrinological Investigation, 39(6), 
pp. 617–625. doi: 10.1007/s40618-015-
0405-5. 
 
Westin, G. (2016) ‘Molecular genetics 
and epigenetics of nonfamilial 
(sporadic) parathyroid tumours’, 
Journal of Internal Medicine, 280(6), 




Aristotle Biomedical Journal, Vol 3, No 2 e-ISSN: 2653-9748 
9 
 
Yamauchi, M. et al. (2001) 
‘Association of polymorphic alleles of 
the calcium-sensing receptor gene with 
the clinical severity of primary 
hyperparathyroidism’, Clinical 
Endocrinology, 55(3), pp. 373–379. 
doi:10.1046/j.1365-265.2001.01318.x. 
 
 
 
 
